Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 3 N=9 Buprenorphine Treatment for Opioid Dependence
Opioid Dependence
Primary: Urine Toxicology for Opiate Use — 2; 4; 2; 0 Participants
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Phase 4 N=54 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Opiate Addiction
Primary: Number of Participants Retained in Treatment — 13; 13 participants — p=0.77
Phase 2 N=90 Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
Opiate Dependence · Chronic Pain
Primary: Pain Intensity — 5.43; 5.92; 5.28; 4.75 units on a scale
Phase 4 N=665 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
Opioid Dependence, on Agonist Therapy
Primary: Number of Patients Reporting Treatment-Emergent Adverse Events — 20; 21 participants
N/A N=300 Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments
Opioid Dependence
Primary: Initiation of Treatment for Opioid Dependence — 85; 74; 63; 75 Participants
Phase 3 N=176 A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
Opioid Dependence
Primary: The Primary Efficacy Endpoint is a Responder Rate Analysis, Where a Responder is Defined as a Patient With no More Than 2 of 6 Months With Any Evidence of Illicit Opioid…
Phase 2 N=38 Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
Opioid-related Disorders
Primary: Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration…
Phase 2 N=4 Benzodiazepine Discontinuation in Opioid Agonist Therapy
Substance Use Disorders
Primary: Participant Acceptability of the Interventions — 1; 0 Participants
N/A N=93 Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function
Chronic Pain
Primary: Mean of the Change in Morphine Dosage (in mg) Required to Achieve 25% Reduction in Thermal Evoked Pain Responses Relative to Baseline (Pre-intervention) Placebo…
Phase 3 N=30 Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
Opioid Dependence
Primary: Successful Induction Onto XR-NTX — 8 Participants
Phase 3 N=653 Prescription Opioid Addiction Treatment Study (POATS)
Opiate Dependence · Substance-related Disorders · Opioid-related Disorders
Primary: The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1 — 19; 24 participants
Phase 3 N=117 Improving Treatment Outcomes for Prescription Opioid Dependence
Drug Dependence
Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77
Phase 2 N=35 Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
Opiate Dependence
Primary: Retention in Treatment — 26 participants
Phase 3 N=227 Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
Opioid Use Disorder
Primary: Subjects With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period-Overall Safety Population — 131; 12; 58; 2 participants
N/A N=52 Feasibility and Preliminary Efficacy of an Opioid Stewardship Program in Hospitalized Patients With Chronic Pain
Opioid Dependence · Chronic Pain
Primary: Number of Participants Screened Compared to Number of Eligible Participants to Determine Feasibility of Recruitment — 97; 62; 351 Participants
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
N/A N=15 Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Substance-Related Disorders
Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…
Phase 3 N=21 Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Opioid Addiction
Primary: Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category — 0.315; 0.328; 0.384; 0.394 Mean default mode network (DMN) z-scores
Phase 3 N=11 A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
Opioid-use Disorder
Primary: Percent of Patients Successfully Transitioned Off Buprenorphine — 2; 3 Participants
Phase 4 N=16 Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.
Addiction Opiate
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 participants
N/A N=78 Completion of OST - a Prospective Study
Opioid Dependence
Primary: Completion of OST — 9 participants